- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
|---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. | ||||||
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 8,220 | +149,09 % | Pre-market Movers: Windtree Therapeutics, Carbon Revolution, BurgerFi International, Everi Holdings, Nature's Miracle Holding | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Windtree Therapeutics, Inc. (WINT) is up over 117%... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 25,010 | -11,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| IMMUNOVANT | 29,100 | +4,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 | Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 11,550 | +10,10 % | DelveInsight Business Research, LLP: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche | The landscape of bispecifics and trispecifics antibodies is rapidly evolving, driven by advancements in immunotherapy and targeted cancer treatments. Biotech companies are racing to develop... ► Artikel lesen | |
| EVOTEC | 8,680 | -0,23 % | Evotec Aktie: Analysten sehen Wendepunkt trotz Kursrückgang | Die Evotec-Aktie verzeichnete in den letzten Handelstagen einen deutlichen Kursrückgang und notierte zuletzt bei 8,61 Euro. Trotz des aktuellen Abwärtstrends zeigen sich Analysten für die Zukunft optimistisch.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,130 | +7,63 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 49,950 | +2,65 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| KINIKSA PHARMACEUTICALS | 26,120 | +0,81 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $405 - $415 million -- Abiprubart... ► Artikel lesen | |
| CG ONCOLOGY | 33,030 | +0,12 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient... ► Artikel lesen | |
| IMMUNOME | 16,510 | +2,99 % | Immunome Reports First Quarter 2024 Financial Results and Provides Business Update | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 44,590 | +4,43 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease | WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
Das Unternehmen SKOTAN SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,79 % bei einem Aktienkurs von 0,219 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SKOTAN SA finden Sie auf Wallstreet Online.
